Old Wegmaster from Yahoo Board
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Obvious question: How do you know? Please remind me of your logic.... Deadlines?
You made a good point earlier about market cap.....
ADXS is so low....compared to what Schwab says are "peers" Got to be undervalued....
ADXS Advaxis Inc $30M --
ACHN Achillion Pharmaceuticals Inc $423M -- -- -- --
IMGN ImmunoGen Inc $397M -- -- -
AGEN Agenus Inc $392M -- --
RIGL Rigel Pharmaceuticals Inc$405M -- --
ANIK Anika Therapeutics Inc $432M
Ditto, crazy day...we lost our gains from early AM....@ 15 mill volume, that would be 225 mill pre RS...big volume...
Great news and we have never really had bad news, science wise. The bummer is that they had to do reverse split...thanks shorts. Does not do any good to say, but I wish they would have given this news a chance to take it above a buck, before doing RS, but I suppose they had to be conservative and time it with the news....$89 apps, my new target. $40 would keep me alive. The volume is through the roof...wonder what it really means....?
James, I am in so deep as I am sure many are.....89/ share is now my breakeven....;( Praying for good news Monday....plus FDA limited hold removed ASAP.... ADXS has been a nightmare. I have no where to go it seems but continue this ride...
Maybe some good news.....what a long road to recovery....for stockholders....“The patients being evaluated for safety and tolerability in Part A all have late-stage disease and have been treated with numerous prior therapies. As a result, we did not expect to observe significant clinical activity in this cohort,” said Andres Gutierrez, M.D. Ph.D., Chief Medical Officer of Advaxis. “Nevertheless, we have seen some encouraging clinical signals to date, including one patient at dose level 1 with non-small cell lung cancer who achieved stable disease after only two doses of ADXS-NEO, which is consistent with rapid immune activation.” He concluded, “This is the first presentation of clinical data from our ADXS-NEO program at a major medical conference.
At this point I can only hope for some good news. RS has never been good, but maybe this one is different. Feeling screwed.....
Up .03 after hours...Volume continues to be 10X a month ago.
Big Volume.....for CREX today....good news!
Guess Board or Message Board? Just the facts, mam. Anyone see Dragnet? I do like hypothesis, but we have too much guessing beyond speculation. Ken may not know what is going to happen...when ink is dry, I am sure they would announce promptly. RS -if and when is a guessing game.
Better not be April Fools...;)
On RS, not all, but most....I want to see some big news like a deal or data and we go over a buck and no RS. Much preferred. I bet volume is averaging 10X previous 10 days...Average Volume (10 Day) 3,319,750, so something is going on to have all this attention/ trading....
Volume average is way up. ADXS is seriously on a higher profile. We are 10X are previous averages... must mean something...I will say good.
I am not a technical trader, but seems was down much of day and then a lot of support came late. I have seen this more lately. With higher volume. Maybe we might weed out some shorts.
One thing is for sure, the volume is huge compared to where we have been. We have market attention.
15 million shares...who bought them...any disclosures? Let's break a buck! NO RS!
I give Ken B credit:
"Net income for the first quarter of fiscal year 2019 was $12.8 million or $0.18 per share, compared with a net loss for the first quarter of fiscal year 2018 of $20.5 million or $0.49 per share. Net cash used during the first quarter ended January 31, 2019 was $12.4 million."
After hours, up 6%, .03.... Over 2 mill shares today, maybe it is time to say goodbye to the shorts....
Results of 55 coming May 2019.....
Thanks- we need some optimisim
I don't see anything negative about the video you posted. They still are there, own that facility and they paid for it. We did get some things we get to keep with all the money raised and spent. It just takes a lo of cash to ride through the slow FDA world in the US.
Great video! Thanks for sharing. I see too many of these without the name Advaxis getting the PR plug we deserve.
Everyone loves a puppy. I guarantee with approval and the story of dogs survival we get major press.
Example:
CBS News Highlights Data from Study with ADXS-cHER2 Immunotherapy for the Treatment of Canine OsteosarcomaOstercoma
https://ir.advaxis.com/video/cbs-news-highlights-data-study-adxs-cher2-immunotherapy-treatment-canine-osteosarcoma
Whether that gets our investment interest up, well I can only hope.
I am not the scientist, but one would think crossing the finish line with a full approval is nothing to sneeze at. Not a ton of money marketwise, but validation and great PR. That would be nice.
We are due a frigin break.....So many positives on our science..".time waits for no-one and it won't wait for me". I am personally rooting for HOT and Canine testimonial.
They have options....but first we get the big deal at the end of March from the conference, stock goes above a buck and beyond. We get cash from the long overdue deal, avoid issuing shares and R/S. The insurance therefore does not happen. Right James? ;)
HOT is HOT, "off the shelf....
Rule 144D SEC, I am sure he had restricted shares. ADXS has to release them and this can be controlled.
This race against time is stressful....we deserve a meaningful good news break...
I have always thought the canine came first and while not the most lucrative, a great profile for PR and validation. Everyone has a soft spot for saving puppies. Like 50% get cancer before age 10...Maybe it is the Purina...
Health
Merck, Pfizer combo treatment boosts kidney cancer survival
Reuters Reuters 7 hours ago
I don't see Advaxis here, but we have to be a player with immunotherapy with LM.... I am not a scientist but will combo prove merit or is that a short term view?
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid
NEW YORK (Reuters) - Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.
Merck said the treatments when used as the initial treatment for advanced renal cell carcinoma (RCC) reduced the risk of death by about 47 percent in its late-stage trial.
The drugs also improved progression-free survival and had a higher response rate in patients than treatment with chemotherapy.Keytruda has been Merck's most important growth driver with its domination of the lucrative lung cancer space, and shows no sign of slowing as it produces positive clinical data and adds approvals for different types of cancer.
Approval of the combination to treat patients with RCC would put Merck again in competition with rival Bristol-Myers Squibb Co's Opdivo, which is already being used in combination with another Bristol-Myers drug, Yervoy, to treat kidney cancer.
Bristol-Myers was a pioneer in pushing treatments that help the immune system attack tumors and Opdivo looked poised to be a top immuno-oncology treatment. But Keytruda's sales have surged past Opdivo's, with Merck expected to sell nearly $10 billion of the drug this year, according to IBES data from Refinitiv.
Up .60 today..... 25% jump...not bad... What is up with Christie purchase?
I like what you say....we did have a 6 mill share day and a 2.5 mill share day....
And I am an old Browns fan. Brian Sipes loss to Plunket Raiders, when he threw an interception on 3rd down instead of them simply of Browns kicking the game winning chip shot. Advaxis needs Joe Montana, he invests.
Tom Brady was like a 6th round draft pick and 3rd string...now look
This week is huge, like I said, Amgen effective termination date will trigger something. So who bought the 2.5 mill shares and who bought that 6 mill a few weeks ago? By Friday COB,, I am really hoping for a new beginning. Call me a pumper, but it only makes sense.
he partnership with Amgen is set to end Feb. 8, 2019. That is Free Agency Day, just like baseball. Lebron went to the Lakers, ADXS will go with _________________________ ? Merck? Bristol Myers?
btw....all the talk on Canine, this was the first and will be the first to make a big PR statement, not $$.
HOT is also hot because it pursues short term need for marketability and cash flow. IMO GLTA
I also think HOT could be the ticket.... 1 H of 2019 things coming
I am impressed with everything but the cash position...
Preclinical data demonstrate that over 90% of neoantigens in an ADXS-NEO vector generated T cell responses that controlled tumor growth1
We could use a break. Amgen was silent the last couple years. We got some good $$, but they dried up as a partner/ resource. We need an active partner with some cash. Praying for good news.
Mark your calendar February 6 and then Amgen termination effective date February 8, FREE AGENCY DAY, just like baseball.
Advaxis to Present an Overview of its Lm Platform and New Information on its Neoantigen-Directed Therapy Programs at the Immuno-Oncology 360° Conference